OBJECTIVES: The Swedish Dental and Pharmaceutical Benefits Agency (TLV) make recommendations on whether outpatient prescription drugs should be publically reimbursed with cost-effectiveness being a key criterion. By contrast, no national economic assessment was traditionally implemented for hospital pharmaceuticals, which were typically individually appraised by each county council. However, since January 2011, a national co-ordinating group of Swedish county councils (NLT) can request that selected in-patient therapies undergo a health economic assessment by the TLV, on which the NLT can conduct price negotiations and issue a national recommendation. This research aims to evaluate which drugs the NLT have been appraising and what the final outcomes were. METHODS: A systematic search for all publically available NLT recommendation documents up to 1^stMay 2015 was undertaken and the drug, date, indication and recommendation, was extracted. RESULTS: CONCLUSIONS: The NLT appears to have successfully implemented a process where significant price pressure is exerted on companies with discounts being frequently secured without being too restrictive over coverage. Could giving other cost-utility HTA bodies negotiating powers help bridge the gap between cost-containment and broadening coverage?